Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30424047 | 1.00 | KDM4E (0.47) | KDM4ETDP1TSHRTP53L3MBTL1 | |
| SCHEMBL29598455 | 0.84 | KDM4E (0.47) | KDM4ETDP1TSHRTP53L3MBTL1 | |
| SCHEMBL605638 | 0.84 | KDM4E (0.47) | KDM4ETDP1TSHRTP53L3MBTL1 | |
| Lithium SCHEMBL31456603 | 0.82 | KDM4E (0.46) | KDM4ETDP1TSHRTP53L3MBTL1 | |
| SCHEMBL3040058 | 0.82 | ERN1 (0.49) | KDM4ETDP1TSHRTP53L3MBTL1 | |
| SCHEMBL28190707 | 0.80 | MCL1 (0.45) | TDP1PTGS2PTPN1HSD17B10ALDH1A1 | |
| SCHEMBL28596875 | 0.80 | CA12 (0.55) | TDP1TSHRL3MBTL1GAAPOLB | |
| SCHEMBL27523131 | 0.80 | KDM4E (0.47) | KDM4ETDP1TSHRTP53L3MBTL1 | |
| SCHEMBL20769195 | 0.80 | CA12 (0.57) | KDM4ETDP1TSHRTP53L3MBTL1 | |
| SCHEMBL31566098 | 0.78 | CDC25B (0.46) | KDM4ETDP1TSHRTP53L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4353759-A1 | PRODUCTION METHOD FOR AQUEOUS FLUORINE-CONTAINING ELASTOMER DISPERSION, COMPOSITION, AND AQUEOUS DISPERSION | Daikin Industries, Ltd. (JP) | 2024-04-17 | — | — | EP | disclosed |
| CN-117529511-A | Method for producing aqueous dispersion of fluoroelastomer, composition, and aqueous dispersion | 大金工业株式会社 | 2024-02-06 | — | — | CN | disclosed |
| US-20230192924-A1 | METHOD FOR PRODUCING FLUORINE-CONTAINING ELASTOMER AQUEOUS DISPERSION AND FLUORINE-CONTAINING ELASTOMER AQUEOUS DISPERSION | DAIKIN INDUSTRIES, LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-4194474-A1 | METHOD FOR PRODUCING AQUEOUS DISPERSION OF FLUORINE-CONTAINING ELASTOMER | Daikin Industries, Ltd. (JP) | 2023-06-14 | — | — | EP | disclosed |
| EP-4186932-A1 | METHOD FOR PRODUCING FLUORINE-CONTAINING ELASTOMER AQUEOUS DISPERSION AND FLUORINE-CONTAINING ELASTOMER AQUEOUS DISPERSION | Daikin Industries, Ltd. (JP) | 2023-05-31 | — | — | EP | disclosed |
| CN-116171291-A | Method for producing aqueous dispersion of fluoroelastomer, and aqueous dispersion of fluoroelastomer | 大金工业株式会社 | 2023-05-26 | — | — | CN | disclosed |
| WO-2022260139-A1 | PRODUCTION METHOD FOR AQUEOUS FLUORINE-CONTAINING ELASTOMER DISPERSION, COMPOSITION, AND AQUEOUS DISPERSION | ダイキン工業株式会社 | 2022-12-15 | — | — | WO | disclosed |
| US-11326006-B2 | Organic thin-film transistor and polymer compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-05-10 | — | — | US | disclosed |
| WO-2022030389-A1 | METHOD FOR PRODUCING AQUEOUS DISPERSION OF FLUORINE-CONTAINING ELASTOMER | ダイキン工業株式会社 | 2022-02-10 | — | — | WO | disclosed |
| WO-2022019241-A1 | METHOD FOR PRODUCING FLUORINE-CONTAINING ELASTOMER AQUEOUS DISPERSION AND FLUORINE-CONTAINING ELASTOMER AQUEOUS DISPERSION | ダイキン工業株式会社 | 2022-01-27 | — | — | WO | disclosed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20050171065-A1 | NAALADas, N-Acetylated-Alpha-Linked-Acidic-Dipeptidase inhibitors; 5-phosphonomethyl-1,3-benzenedicarboxylic Acid; glutamate abnormalities, anticancer, antidiabetic agent, angiogenesis inhibitor, neuropathy, pain, compulsive disorders, prostate diseases, glaucoma | GUILFORD PHARMACEUTICALS INC. | 2005-08-04 | — | — | US | disclosed |
| US-20050080139-A1 | Naaladase inhibitors for treating huntington's disease | GUILFORD PHARMACEUTICALS INC. | 2005-04-14 | — | — | US | disclosed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | disclosed |
| US-6452044-B2 | NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-09-17 | — | — | US | disclosed |
| US-20020019430-A1 | Nervous system and psychological disorders | EISAI INC. | 2002-02-14 | — | — | US | disclosed |
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | GUILFORD PHARMACEUTICALS INC., A DELAWARE CORPORATION | 2002-01-31 | — | — | US | disclosed |
| CN-1205698-A | Heterocyclyl-condensed benzoylguanidines, their prodn. and use as inhibitors of cellular Na+/H+-antiporter | MERCK PATENT GES MIT BESCHR KT (DE) | 1999-01-20 | — | — | CN | disclosed |
| WO-1996034851-A1 | BENZENE, PYRIDINE, NAPHTALENE OR BENZOPHENONE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-11-07 | — | — | WO | disclosed |
| US-4042750-A | COATINGS, MOLDING MATERIALS | STANDARD OIL COMPANY (INDIANA) (US) | 1977-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | SMN1; SMN2, GAA, NAALAD2 | KDM4E 1863/4885TDP1 62/4885TSHR 4825/4885 |
| US-20050080139-A1 | Naaladase inhibitors for treating huntington's disease | HTT, GAA, ADA | KDM4E 2554/4885TDP1 27/4885TSHR 3380/4885 |
| US-20050171065-A1 | NAALADas, N-Acetylated-Alpha-Linked-Acidic-Dipeptidase inhibitors; 5-phosphonomethyl-1,3-benzenedicarboxylic Acid; glutamate abnormalities, anticancer, antidiabetic agent, angiogenesis inhibitor, neuropathy, pain, compulsive disorders, prostate diseases, glaucoma | NAALAD2, GLUL, DNPEP | KDM4E 3314/4885TDP1 296/4885TSHR 4610/4885 |
| US-20020019430-A1 | Nervous system and psychological disorders | GLUL, DDC, DNPEP | KDM4E 2369/4885TDP1 533/4885TSHR 4664/4885 |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | ALDH1A2, GAA, PDE6A | KDM4E 2355/4885TDP1 125/4885TSHR 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.